Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. (2026) Schmid P, Cortes J, Dent RA, McArthur HL, Pusztai L, Kuemmel S, Denkert C, et al. Journal article The SURVIVE study: Re-evaluating follow-up in early breast cancer. (2026) Huesmann ST, Friedl TW, Pfister K, Schäffler H, Fink A, Braun T, Mehmeti F, et al. Journal article Interception of molecular relapse in breast cancer: The SURVIVE HERoes study (NCT06643585). (2026) Janni W, Friedl TW, Huesmann ST, Rack B, Heublein S, Schäffler H, Mehmeti F, et al. Journal article Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. (2026) Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, et al. Journal article Reply to: “Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology, ” “Key Methodological Considerations in the Interpretation of the CONKO-007 Trial, ” and “Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer” (2026) Fietkau R Journal article Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. (2026) Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, et al. Journal article, Erratum A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: A report by the RANO resect group. (2025) Karschnia P, Young JS, Wijnenga M, Wagner A, Schnell O, Häni L, Esquenazi Y, et al. Journal article Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. (2025) Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, et al. Journal article Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial (2025) Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, et al. Journal article Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients (2025) Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kähler K, Hauschild A, et al. Journal article